

## DAFTAR PUSTAKA

- Afzal S, Masroor I, Beg M. Evaluation of Chronic Liver Disease: Does Ultrasound Scoring Criteria Help? *Int J Chronic Dis.* 2013;2013(July):1–5.
- Ahadi S, Gharekhani A, Shiva A. Treatments of nonalcoholic fatty liver disease in adult who have nootherill ness: areviewarticle. *Arab J Gastroenterology.* 2019.
- Albhaisi S, Sanyal A. Recentadvances in understanding and managing non alcoholic fatty liver disease. *F1000 Research.*2018
- Alempijevic T, Zec S, Nikolic V et al. 2017. Doppler ultrasonography combined with transient elastography improves the non-invasive assessment of fibrosis in patients with chronic liver disease. *Med Ultrason, Vol 19, no.1,* 7-15
- Alizadeh A, Mansour F, Joukar AR, SepehrimaneshM, HojatiSA, MansourA. LaboratoryTests, Liver Vessels Color Doppler Sonographyand Fibroscan Findings in Patient swith Nonalcoholic Fatty Liver Disease: An Observation Study. *J of ClinImagingScie.*2018
- Atherosclerosis.* 2015.
- Barr RG, Ferraioli G, Palmeri ML, et al. 2015. Elastography Assesment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. *Radiology.rsna.org.* Volume 276:number 3

- Benedict M, Zhang X, Benedict M, Zhang X. Non-alcoholic fatty liver disease : An expanded review. 2017;9(16):715–32.
- Borges V, Diniz AL, CotrimHP, Rocha HL, SalomaoFC. Hepatic Vein Doppler Flowmetry in Patient swith Nonalcoholic Steatosis. *RadiolBras*.2011
- Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in nonalcoholic fatty liver disease. *World J Gastroenterol*. 2020;26(39):5919–43.
- CasteraL, Rust MF, Loomba R. Noninvasive Assessment of Liver Disease in Patient swith Nonalcoholic Fatty Liver Disease. *Gastroenterology*.2019
- Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67(1):328–57.
- Choong C-C, Venkatesh SK, Siew EPY. Accuracy of Routine Clinical Ultrasound for Staging of Liver Fibrosis. *J Clin Imaging Sci*. 2012;2(3):58.
- Churchill Living stone Elsevier, edisi ke 3,hal.152.
- Cicero G, D’angelo T, Racchiusa S, Salamone I, Visalli C, Bottari A, et al. Cross-sectional imaging of parotid gland nodules: A brief practical guide. *J Clin Imaging Sci*. 2018;8(1).
- Cross, Sarah J. Linker, Kay E. Leslie FM. 乳鼠心肌提取 HHS Public Access. *Physiol Behav*. 2016;176(1):100–106.

David L. Coy, et al 2015. Body CT: The Essential. McGraw Hill Education, Medical.

Hal103-105

Davoudi Y, Layegh P, Sima H, Tatari S, Faghani R. Diagnostic Value of

Conventional and Doppler Ultrasound Findings in Liver Fibrosis in Patients

with Chronic Viral Hepatitis. J Med Ultrasound [Internet].

2015;23(3):123–8.

Available

from:

<http://dx.doi.org/10.1016/j.jmu.2014.10.002>

de Almeida e Borges VF, Diniz ALD, Cotrim HP, Rocha HLOG, Salomão FC. Hepatic

vein Doppler flowmetry in patients with nonalcoholic steatosis. Radiol

bras. 2011;44(1):1–6.

de Lédinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol

Clin Biol [Internet]. 2008;32(6 SUPPL. 1):58–67. Available from:

[http://dx.doi.org/10.1016/S0399-8320\(08\)73994-0](http://dx.doi.org/10.1016/S0399-8320(08)73994-0)

Dean Alexander Mcnaughton dan Monzer M Abu-Yousef, 2011. Doppler US of

The Liver Made Simple. Gastrointestinal Imaging, RSNA.

DrescherHK, Weiskirchen S, Weiskirchen R. Current status in testing for non

alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis

(NASH. *Cells*. 2019

DumitrascuDL, Neuman MG. Non alcoholic fatty liver disease: an update on

diagnosis. *ClujulMed*.2018

El-hariri, Mona et al. 2017. “The Egyptian Journal of Radiology and Nuclear

Medicine Diagnostic Value of Transient Elastography ( Fibroscan ) in the

Evaluation of Liver Fibrosis in Chronic Viral Hepatitis C : Comparison to Liver Biopsy." *The Egyptian Journal of Radiology and Nuclear Medicine* 48(2): 329–37. <http://dx.doi.org/10.1016/j.ejrm.2017.03.026>.

Enomoto M, Morikawa H, Tamori A, Kawada N. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. *World J Gastroenterol.* 2014;20(34):12031–8.

Ergelen R, Yilmaz Y, Asedov R, Celikel C, Akin H, Bugdayci O, et al. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis. *Abdom Radiol.* 2016;41(8):1505–10.

Gastroenterological Society of Australia. Fatty Liver Disease. 2011. Available from url: [www.gesa.org.au](http://www.gesa.org.au) . Access on Oct 25th, 2019.

Gerstenmaier JF, Gibson RN. *Ultrasound in chronic liver disease.* 2014;441–55.

Gupta N, Raj K, Chandra R, Malik A, Bagri N, Thakur N. Relationship between greyscale sonographic grades of fatty liver and shearwave elastographic values: an observational study. *Int J Res Med Sci.* 2019

Hashemi S A, Alavian SM, Fesharaki MG. Assessment of transient elastography (fibroscan) for diagnosis of fibrosis in non alcoholic fatty liver disease: a systematic review and meta analysis. *Caspian J Intern Med.* 2016

Hashimoto E, Tokushige K, Ludwig J. Diagnosis and Classification of Non Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Concepts and Remaining Challenges. *Hepatology.* 2014

- Horowitz JM, Venkatesh SK, Ehman RL, Jhaveri K, Kamath P, Ohliger MA, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Vol. 42, *Abdominal Radiology*. 2017. 2037–2053 p.
- Iruzubieta P, Gonzalez M, Cabezas J, Loste MT, Crespo J. Diagnosis and characterization of non alcoholic fatty liver disease. *LiverResClinMan*.2018.
- Iser D, Ryan M. Fatty liver disease a practical guide for GPs. *Aust Fam Physician*.2013Jul;42(7):444-7.
- Ismail A, Dumitraşcu DL. Cardiovascularrisk in fatty liverdisease: the liver-heartaxis-literaturereview. *Front.Med*. 2019 Sept 13;6:202.
- Kamali L, Adibi A, Ebrahimian S, JafariF, Sharifi M. Diagnostic Performance of Ultrasonography in Detecting Fatty Liver Disease in Comparison with Fibroscan in People Suspected of Fatty Liver. *WoltersKluwer*.2019
- Kelly N, Wattacheril J. Nonalcoholic Fatty Liver Disease: Evidence-Based Managementand Early Recognition of Nonalcoholic Steatohepatitis. *Elsevier*. 2019. Doi:<https://doi.org/10.1016/j.nurpra.2019.06.008>
- Khoonsari M, Azar MM, Ghavam R, HaytamiK, Asohar M, Gholami A, et al. Clinical mani festati on sand diagnosis of nonalcoholic fatty liver disease. *IranJ Pathol*. 2017
- Ledinghen VD, Vergniol J. 2008. Transient elastography (Fibroscan). *Elsevier*. *GastroenterolClin Bio* 32, 58-67

- Lupsor M, Platon. Noninvasive evaluation of fibrosis and steatosis in nonalcoholic fatty liver disease by elastographic methods. 2018
- Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, et al. Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. *Int J Organ Transplant Med.* 2016;7(3):149–60.
- Moon KM, Kim G, Baik SK, Choi E, Kim MY, Kim HA, et al. Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. 2013;389–98.
- Myron A, Pozniak and Paul L. Allan, 2014. *Clinical Doppler Ultrasound.*
- Nishiura T, Watanabe H, Ito M, Matsuoka Y, Yano K. Ultrasound evaluation of the fibrosis stage in chronic liver disease by the simultaneous use of low and high frequency probes. 2005;78(March):189–97.
- Olteanu AV, Balan G, Golongan E, Balan G, Trifan A. Utility of doppler ultrasound portal vein velocity measurement in the evaluation of non alcoholic fatty liver disease: a case base approach of the literature. *Int J of Med Dentistry.* 2016
- Pappachan JM, Babu S, Krihnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. *J Clin Transl Hepatol* 2017;5(4):384-393. DOI: 10.14218/JCTH.2017.00013.
- Perazzo, Hugo et al. 2015. "Factors That Could Impact on Liver Fibrosis Staging by Transient Elastography." 2015.

- Pirmoazen AM, Khurana A, Kaffas A El, Kamaya A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. *Theranostics*. 2020;10(9):4277–89.
- Saeed A, Khan M, Morrissey S, Kane D, Fraser AD. Impact of outpatient clinic ultrasound imaging in the diagnosis and treatment for shoulder impingement: A randomized prospective study. *Rheumatol Int*. 2014;34(4):503–9.
- Setiati S, Alwi I, Sudoyo AW, Marcellus SK, Setiyohadi B, Syam AF. *Buku Ajar Ilmu Penyakit Dalam*. Ed VI. Jakarta:InternalPublishing;2014.
- Sherstha MK, Ghartimagar D, Ghost A, Sathian B. Hepatic vein spectral doppler wave form in patient with fatty liver changes—a study from Western Nepal. *MedSci*. 2014.
- Singh D, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: a road less travelled. *Ind J Endo Met*. 2013
- Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): Where does it stand in the United States practice. *Clin Gastroenterol Hepatol* [Internet]. 2015;13(1):27–36. Available from: <http://dx.doi.org/10.1016/j.cgh.2014.04.039>
- Tarzamni MK, Khoshbaten M, Sadrarhami S, Daneshpajouhnejad P, Jalili J, Gholamian M, et al. Hepatic artery and portal vein doppler indexes in non-alcoholic fatty liver disease before and after treatment to prevent unnecessary health care costs. *Int J Prev Med*. 2014;5(4):472–7.

- Than NN, Newsome PN. A concisereview of non alcoholic fatty liver disease.
- Ulusan S, Yakar T, Koc Z. Evaluationof Portal Venous Velocity with Doppler  
Ultrasoundin Patient swith Nonalcoholic Fatty Liver Disease. *Korean  
JRadiol.* 2011
- Wang XJ, MalhiH. In theclinic® nonalcoholicfatty liverdisease. *Ann Intern Med.*  
2018 Nov 6;169(9):ITC65-ITC80. DOI:10.7326/AITC201811060.
- Weiß J, Rau M, Geier A. Nichtalkoholische fettlebererkrankung: Epidemiologie,  
verlauf, diagnostik und therapie. *Dtsch Arztebl Int.* 2014;111(26):447–52.
- Wilkins T, TadmokA, Hepburn I, Schade RR. Non alcoholic fatty liver  
disease:diagnosis and management. *American Family Physician.*2013.
- Xiao L, Xian J, Li Y, et al. 2014. Parameters associated with significant liver  
histological changes in patients with chronic hepatitis B. ISRN  
*Gastroenterol*:913890
- Zhang G, Zhao Q, LinC, Hu Z, ZhangT, Gao Z. Transient Elastography and  
Ultrasonography: Optimal Evaluation of Liver Fibrosisand Chirrosisin  
Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty  
Liver Disease. *Bio Med Research Int.* 2019  
<https://www.racgp.org.au/download/Documents/AFP/2013/July/201307iser.pdf>

f



Zheng RQ, Wang QH, Lu M De, Xie S Bin, Ren J, Su ZZ, et al. Liver fibrosis in chronic viral hepatitis: An ultrasonographic study. *World J Gastroenterol.* 2003;9(11):2484–9.

Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease: Current Evidence and Practice. *World J of Gastroenterology.* 2019

## LAMPIRAN I



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
KOMITE ETIK PENELITIAN KESEHATAN  
RSPTN UNIVERSITAS HASANUDDIN  
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari., M.Med., Ph.D., SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

### REKOMENDASI PERSETUJUAN ETIK

Nomor : 484/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 28 Juli 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21060396	No Sponsor Protokol	
Peneliti Utama	<b>dr. Gerda Widya Nengsi</b>	Sponsor	
Judul Peneliti	Kesesuaian ultrasonography grayscale dan doppler dengan fibroskan dalam mendeteksi fibrotik hepar pada pasien non alcoholic fatty liver disease		
No Versi Protokol	<b>1</b>	Tanggal Versi	<b>23 Juni 2021</b>
No Versi PSP	<b>1</b>	Tanggal Versi	<b>23 Juni 2021</b>
Tempat Penelitian	<b>RS Dr. Wahidin Sudirohusodo Makassar</b>		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>28 Juli 2021</b> sampai <b>28 Juli 2022</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med., Ph.D., Sp.GK (K)</b>	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

**LAMPIRAN II**

**PERSETUJUAN SETELAH PENJELASAN  
(Informed Consent)**

Saya yang bertanda tangan dibawah ini, orang tua/wali :

Nama :  
Umur/Kelamin :  
Alamat :

Dengan ini menyatakan dengan sesungguhnya serta memberikan persetujuan dan bersedia menjalani atau mengikuti penelitian ini setelah mendapat penjelasan dari peneliti (dokter) dan mengerti sepenuhnya tentang prosedur penelitian yang akan dilakukan.

Demikian pernyataan ini saya buat dengan penuh kesadaran tanpa paksaan dari pihak manapun.

Tanggal:.....

Saksi-saksi

Yang Membuat Pernyataan

Tanda tangan :

1.

(.....)

(.....)

2.

(.....)

-----

Tempat meminta penjelasan:

Pejabat Peneliti Pejabat Medis (dr. yang merawat)

Nama : dr. Gerda Widya Nengsi

Alamat : Royal Spring blok B5 no 15

Telepon (HP) : 08114206610

Penanggungjawab Medis : Prof. Dr.dr. Bachtiar Murtala, Sp.Rad(K)

Alamat : Jl. Raya Pendidikan Komp. UNM, Makassar

Telepon (HP) : 08114444920

### LAMPIRAN III

#### Data dan Sampel penelitian

No	Nama	JK	umur	MPPV	Scoring SWE	Scoring fibroscan	Ukuran hepar	Permukaan	Tepi	Echo parenkim	Diameter MPV/ RHV
1.	M.A	Lk	33	14.8	9,9 (F>2)	14,0(F>3)	membesar	reguler	tumpul	meningkat	0,61
2.	H	Pr	39	18	6,7 ( F>1)	7,4(F>1)	membesar	reguler	tajam	meningkat	0,57
3.	V	Pr	45	15	7,0 (F>1)	7,2 (F>1)	normal	reguler	tajam	meningkat	0,76
4.	F	Pr	40	16	4,8 (F>0)	5,1 (F>0)	normal	reguler	tajam	homogen	0,42
5.	P.B	Lk	62	17.4	6,5 (F>1)	6,2 (F>1)	normal	reguler	tajam	meningkat	0,44
6.	N.I	Lk	39	16.4	4,8 (F>0)	4,0 (F>0)	normal	reguler	tajam	meningkat	0,51
7.	A.U	Lk	58	18	9,8 (F>3)	13,2 (F>3)	membesar	reguler	tumpul	meningkat	0,6
8.	K.H	Pr	60	18	7,6 (F>1)	7,0(F>1)	normal	reguler	tajam	meningkat	0,58
9.	H.A	Lk	38	18	8,6 (F>2)	9,1(F>2)	normal	reguler	tajam	meningkat	0,56
10.	Y.N	Pr	67	19	5,9 (F>1)	6,8(F>0)	normal	reguler	tajam	homogen	0,46
11.	R.N	Pr	41	19.7	5,6 (F>1)	4,0(F>0)	normal	reguler	tajam	homogen	0,51
12.	Y.L	Lk	39	17	5,2 (F>0)	7,1 (F>1)	normal	reguler	tajam	meningkat	0,58
13.	S.R	Pr	46	18	8,7 (F>2)	10,3(F>2)	normal	reguler	tajam	meningkat	0,47
14.	F.N	Lk	43	16	3,3 (F>0)	3,1(F>0)	normal	reguler	tajam	homogen	0,59
15.	I.R	Lk	42	19	5,2 (F>0)	3,8(F>0)	normal	reguler	tajam	homogen	0,55
16.	A.W	Lk	51	16	5,3 (F>0)	7,2(F>1)	normal	reguler	tajam	meningkat	0,58
17.	N.S	Lk	53	17	3,3 (F>0)	4,8 (F>0)	normal	reguler	tajam	homogen	0,46
18.	A.N.I	Pr	36	18	8,6 (F>2)	9,3(F>2)	normal	reguler	tajam	meningkat	0,52
19.	N.H	Lk	68	15	9,9(F>3)	12,4(F>3)	membesar	reguler	tumpul	meningkat	0,65
20.	W.P.I	Pr	39	19	9,5 (F>2)	11,0 (F>3)	normal	reguler	tajam	meningkat	0,48
21.	A.D	Lk	41	19	9,7 (F>2)	7,1 (F>1)	normal	reguler	tajam	meningkat	0,53
22.	S.W	Pr	54	14	8,6 (F>2)	12,9 (F>3)	membesar	reguler	tumpul	meningkat	0,66
23.	T.F	Lk	44	18	4,5 (F>0)	5,1 (F>0)	normal	reguler	tajam	homogen	0,43
24.	M.P	Lk	65	19	5,6 (F>1)	5,3 (F>0)	normal	reguler	tumpul	meningkat	0,65
25.	M.C	Lk	58	17	7,7 (F>2)	11,8(F>3)	normal	reguler	tajam	meningkat	0,63
26.	S.R	Pr	53	18	5,3 (F>0)	3,7 (F>0)	normal	reguler	tajam	homogen	0,51
27.	A.N	Lk	61	19	9,8 (F>3)	12,8(F>3)	membesar	reguler	tumpul	meningkat	0,54
28.	R.M	Lk	67	17	7,8 (F>2)	9,3 (F>2)	normal	reguler	tajam	meningkat	0,66
29.	J.S	Lk	31	16	7,6 (F>1)	8,1(F>2)	normal	reguler	tajam	meningkat	0,53
30.	W.R	Pr	34	18	6,1 (F>1)	4,7(F>0)	normal	reguler	tajam	meningkat	0,47
31.	B.R	Lk	39	18	6,5 (F>1)	7,9 (F>2)	normal	reguler	tajam	meningkat	0,68
32.	S.R	Pr	58	17	4,0 (F>0)	4,5 (F>0)	membesar	reguler	tajam	homogen	0,59

## LAMPIRAN IV

### CURRICULUM VITAE

#### 1. Data Pribadi

1. Nama : dr.Gerda Widya Nengsi
2. Agama : Islam
3. Tempat/tanggal lahir : Palopo, 23 Oktober 1986
4. Alamat : Jalan Tun Abdul Razak. Komp.Royal  
Spring blok B5 no 15. Makassar
5. Nama Ayah/Ibu : H. Nawir Syarif / Hj.St.Madyang
6. Saudara kandung : dr.Nasaruddin Nawir., Sp.OG
7. Status Sipil : Menikah

#### II. Riwayat Pendidikan

1. SD : SD Negeri 81 Palopo, tahun lulus 1998
2. SMP : SMP Negeri 1 Palopo, tahun lulus 2001
3. SMA : SMA Negeri 1 Palopo, tahun lulus 2004
4. Pergurun tinggi : Fakultas Kedokteran Universitas Muslim  
Indonesia, tahun 2004
5. Profesi Dokter : Fakultas Kedokteran Universitas Muslim  
Indonesia, tahun lulus 2012
6. PPDS : Bagian Radiologi Fakultas Kedokteran  
Universitas Hasanuddin periode Juli  
2017

#### III. Riwayat Pekerjaan :

1. RSUD St.Madyang, dokter jaga IGD tahun 2014-2017, Kota Palopo
2. RSIA Bahagia, dokter jaga IGD tahun 2014-2015, Kota Makassar
3. Dosen Non PNS UIN Alauddin periode tahun 2014-2021

#### IV. Makalah kongres nasional perhimpunan dokter spesialis radiologi XIII di bali "

**VOLVULUS SIGMOID"**